|
시장보고서
상품코드
2117815
망막용 바이오시밀러 시장 규모, 점유율, 성장 분석 : 분자별, 적응증별, 유통 채널별, 최종사용자별, 투여 경로별, 지역별 - 업계 예측(2026-2033년)Retinal Biosimilars Market Size, Share, and Growth Analysis, By Molecule (Ranibizumab Biosimilars, Aflibercept Biosimilars), By Indication, By Distribution Channel, By End User, By Route of Administration, By Region - Industry Forecast 2026-2033 |
||||||
세계의 망막용 바이오시밀러 시장 규모는 2024년에 8억 6,420만 달러로 평가되며, 2025년 10억 2,494만 달러에서 2033년까지 40억 1,215만 달러로 확대되어, 예측 기간(2026-2033년) 동안 CAGR 18.6%로 성장할 것으로 전망됩니다.
세계 망막용 바이오시밀러는 노화성 황반변성 및 당뇨병성 망막병증 등의 질환 치료에 큰 진전을 가져오고 있으며, 고가의 항VEGF제를 대체할 수 있는 효과적인 생물학적 제제 옵션을 제공하고 있습니다. 의료 제도에 대한 재정적 압박이 커지는 가운데, 1회 주사당 2,000달러를 초과하는 원료약의 터무니없는 비용이 추가적인 부담으로 작용하며 이 시장의 발전을 가속화하고 있습니다. 최근 규제 당국의 승인을 계기로 각 기업은 연구개발(R&D) 노력을 강화하는 한편, 개발 비용을 최소화하기 위해 노력하고 있습니다. 또한, 치료 효과를 저해하지 않으면서 바이오시밀러 도입에 따른 극적인 가격 인하가 보여주듯이, 비용 대비 효과가 높은 치료법을 우선시하는 지불자 측의 동향이 변화하고 있어 바이오시밀러에 대한 수용도가 높아지고 있음이 부각되고 있습니다. 가격이 합리적으로 낮아짐에 따라 사용량이 증가할 것으로 예상되며, 이는 의료 종사자 및 규제 당국에 풍부한 시판 후 데이터를 제공하는 선순환을 만들어내어 바이오시밀러의 가치를 한층 더 높일 것입니다.
세계 망막용 바이오시밀러 시장의 성장요인
세계 망막용 바이오시밀러 시장은 높은 유효성 기준을 유지하면서 비용 대비 효과가 높은 치료 솔루션에 대한 수요 증가에 힘입어 크게 성장하고 있습니다. 환자와 의료 시스템은 품질을 저하시키지 않는 대체품을 원하고 있으며, 이에 따라 제약사들은 바이오시밀러의 개발과 도입을 가속화하고 있습니다. 이러한 추세는 안과 진료 현장에서 바이오시밀러에 대한 인지도를 높이고, 의료진이 바이오시밀러를 참조 의약품의 신뢰할 수 있는 대체품으로 인식하도록 유도하여, 결과적으로 처방 의욕을 높이고 있습니다. 그 결과, 바이오시밀러에 대한 신뢰가 높아짐에 따라 건강보험 사업자의 수용도도 높아지고 있으며, 이 분야의 투자와 혁신이 선순환을 이루고 있습니다.
세계 망막용 바이오시밀러 시장의 제약요인
세계 망막용 바이오시밀러 시장은 주로 선발 기업이 보유한 기존 특허로 인해 중대한 과제에 직면해 있습니다. 이러한 특허는 복잡한 소송 절차를 유발하여 바이오시밀러 제품의 시장 진입을 제한하고 있습니다. 이러한 법적 장벽을 극복하기 위해서는 막대한 자금 투입과 전략적인 계획이 필요하며, 이는 중소기업의 시장 진입을 저해하는 요인이 될 수 있습니다. 그 결과, 제품 출시가 지연되어 의료 종사자와 환자의 선택지가 제한될 수밖에 없습니다. 또한, 현재의 시장 역학으로 인해 기존 치료제의 가격이 높은 수준을 유지하는 경향이 있어, 헬스케어 분야에서 망막용 바이오시밀러의 성장과 확대 가능성을 더욱 제약하고 있습니다.
세계 망막용 바이오시밀러 시장 동향
세계 망막용 바이오시밀러 시장에서는 각 지역의 규제 당국이 바이오시밀러 제품의 승인 체계를 조화시켜 나감에 따라, 규제 경로의 조화를 향한 뚜렷한 동향이 나타나고 있습니다. 이러한 움직임으로 인해 중복되는 데이터 요건이 줄어들고 승인 절차가 간소화되면서 제품 출시가 가속화되고 있습니다. 기업들은 현재 다양한 지역에서 통일된 임상 자료를 활용할 수 있게 되어 개발 비용과 기간을 대폭 절감하고 있습니다. 이러한 효율화를 통해 기업들은 자원을 지리적 확장 및 타겟 마케팅 활동에 재분배할 수 있게 되었으며, 이는 궁극적으로 전 세계 환자에게 망막용 바이오시밀러의 가격 경쟁력을 높이고 접근성을 개선하며, 결과적으로 시장 경쟁을 강화하는 결과를 가져올 것입니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 망막용 바이오시밀러 시장 규모 : 분자별
세계의 망막용 바이오시밀러 시장 규모 : 적응증별
세계의 망막용 바이오시밀러 시장 규모 : 유통 채널별
세계의 망막용 바이오시밀러 시장 규모 : 최종사용자별
세계의 망막용 바이오시밀러 시장 규모 : 투여 경로별
세계의 망막용 바이오시밀러 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.27Global Retinal Biosimilars Market size was valued at USD 864.2 Million in 2024 and is poised to grow from USD 1024.94 Million in 2025 to USD 4012.15 Million by 2033, growing at a CAGR of 18.6% during the forecast period (2026-2033).
Global retinal biosimilars represent a significant advancement in the treatment of conditions like age-related macular degeneration and diabetic retinopathy, providing effective biological alternatives to costly anti-VEGF drugs. The rising financial pressures on healthcare systems, compounded by the exorbitant costs of originator biologics exceeding $2,000 per injection, have accelerated the development of this market. Recent regulatory approvals are prompting companies to enhance their R&D initiatives while minimizing development expenses. Furthermore, an evolving payer landscape prioritizing cost-effective therapies, evidenced by dramatic price reductions linked to biosimilar adoption-without compromising treatment efficacy-highlights their growing acceptance. As affordability increases, usage is expected to rise, creating a positive feedback loop that provides substantial post-marketing data for healthcare professionals and regulators, reinforcing the biosimilars' value.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Biosimilars market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Retinal Biosimilars Market Segments Analysis
Global retinal biosimilars market is segmented by molecule, indication, distribution channel, end user, route of administration and region. Based on molecule, the market is segmented into Ranibizumab Biosimilars, Aflibercept Biosimilars and Other Anti-VEGF Biosimilars. Based on indication, the market is segmented into Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion and Diabetic Retinopathy. Based on distribution channel, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end user, the market is segmented into Hospitals and Ophthalmology Clinics. Based on route of administration, the market is segmented into Intravitreal Injection. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Retinal Biosimilars Market
The global retinal biosimilars market is significantly driven by the growing demand for cost-effective treatment solutions that maintain high standards of efficacy. Patients and healthcare systems are seeking alternatives that do not compromise on quality, prompting manufacturers to accelerate the development and introduction of biosimilars. This trend enhances their visibility within ophthalmology practices and encourages healthcare professionals to view biosimilars as reliable substitutes for reference drugs, thereby increasing their willingness to prescribe them. Consequently, as confidence in biosimilars rises, so does the acceptance from health insurance providers, fostering a positive cycle of investment and innovation in this sector.
Restraints in the Global Retinal Biosimilars Market
The Global Retinal Biosimilars market faces significant challenges primarily due to the legacy patents held by originator companies, which create complicated litigation processes that restrict the entry of biosimilar products. These legal hurdles necessitate considerable financial investment and strategic planning, which can discourage smaller firms from entering the market. Consequently, this results in postponed product launches and a limited variety of choices for healthcare professionals and patients. Moreover, the prevailing market dynamics often sustain elevated pricing for existing therapies, further constraining the potential for growth and expansion of retinal biosimilars in the healthcare landscape.
Market Trends of the Global Retinal Biosimilars Market
The Global Retinal Biosimilars market is experiencing a significant trend toward the harmonization of regulatory pathways, as regional authorities align their frameworks for approving biosimilar products. This development is streamlining the approval process by reducing overlapping data requirements, which in turn accelerates product launches. Companies can now utilize a unified clinical dossier across various regions, substantially lowering development costs and time. This efficiency allows organizations to redirect resources towards geographic expansion and targeted marketing efforts, ultimately resulting in more favorable pricing and improved accessibility of retinal biosimilars for patients worldwide, thereby enhancing market competitiveness.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Retinal Biosimilars Market Size by Molecule & CAGR (2026-2033)
- Market Overview
- Ranibizumab Biosimilars
- Aflibercept Biosimilars
- Other Anti-VEGF Biosimilars
Global Retinal Biosimilars Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Age-Related Macular Degeneration
- Diabetic Macular Edema
- Retinal Vein Occlusion
- Diabetic Retinopathy
Global Retinal Biosimilars Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
Global Retinal Biosimilars Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Ophthalmology Clinics
Global Retinal Biosimilars Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravitreal Injection
Global Retinal Biosimilars Market Size & CAGR (2026-2033)
- North America (Molecule, Indication, Distribution Channel, End User, Route of Administration)
- US
- Canada
- Europe (Molecule, Indication, Distribution Channel, End User, Route of Administration)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Molecule, Indication, Distribution Channel, End User, Route of Administration)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Molecule, Indication, Distribution Channel, End User, Route of Administration)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Molecule, Indication, Distribution Channel, End User, Route of Administration)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Samsung Bioepis Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celltrion, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz Group AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocon Biologics Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fresenius Kabi AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Formycon AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alvotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- STADA Arzneimittel AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Coherus BioSciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Organon & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shanghai Henlius Biotech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Thera Solutions Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mabxience Holding S.L.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Reliance Life Sciences Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LG Chem Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
